<DOC>
	<DOCNO>NCT02326441</DOCNO>
	<brief_summary>The purpose study determine safety tolerability study drug KX2-361 determine much study drug enters bloodstream , patient advance malignancy respond conventional therapy .</brief_summary>
	<brief_title>Safety , Tolerability &amp; PK KX2-361 Subjects w Adv . Malignancies Refractory Conventional Therapies</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>1 . Signed write informed consent . 2 . Adults ≥ 18 year age . 3 . Dose Escalation Cohort : Confirmed advance solid tumor lymphoma standard curative palliative measure exist longer effective ; subject progressive brain metastasis also eligible . OR Confirmed Histological/cytological hematological malignancy refractory to/relapsed and/or intolerant standard therapy standard therapy exists . OR Confirmed high grade glioma ( grade 3and4 ) relapsed/refractory standard therapy progressive disease follow radiation therapy . Patients number prior treatment allow . Expansion Cohort : Patients high grade glioma ( grade 3 4 ) refractory standard therapy , progressive disease follow radiation therapy . Patients number prior treatment allow . 4 . ECOG performance status 02 , Karnofsky Performance Status ≥60 ( glioma subject ) . 5 . Life expectancy least 12 week . 6 . The following laboratory value : ANC ≥ 1.5 x 10⁹/L Platelets ≥ 100 x 10⁹/L Hemoglobin ( Hgb ) &gt; 10 g/dL Serum total bilirubin ≤ 1.5 x ULN ALT AST ≤ 3.0 x ULN ( subject know liver metastasis may AST ALT ≤ 5.0 x ULN ) Serum creatinine ≤ 1.5 x ULN calculate creatinine clearance ( use Cockcroft Gault method ) &gt; 60 mL/min ) 7 . Willingness use acceptable birth control . Subjects potential pregnancy impregnate partner must agree follow acceptable birth control method avoid conception . Female subject childbearing potential must negative pregnancy test . 1 . Subjects recover Grade 0 1 toxicity previous anticancer treatment previous investigational agent . 2 . Subjects receive investigational agent within 28 day first day study drug . 3 . Subjects primary CNS malignancy high grade glioma ( Grade 3 4 ) 4 . Subjects receive extensive radiation therapy , include sternum , pelvis , scapula , vertebra skull , within 4 week first day study drug receive palliative low dose radiation therapy limit limb within 1 week first day study drug , subject recover side effect therapy . 5 . Subjects currently take receive hormone ( eg , estrogen progesterone ) within 7 day first dose study drug . Note : Luteinizing hormonereleasing hormone ( LHRH ) analogs permissible . 6 . Subjects use moderate strong CYP450 3A4 modulators ( exception antifungal agent list Appendix 2 ) within 5 halflives first dose study drug . 7 . Subjects use prescription OTC medication ( include , example , proton pump inhibitor , H2 antagonists calcium carbonate ) reduce neutralize gastric acidity within 5 half life first dose study drug . Use medication supportive care cycle 1 permit . 8 . Subjects major surgery within 4 week first day study drug . 9 . Subjects major surgery upper gastrointestinal tract , history inflammatory bowel disease , malabsorption syndrome , medical condition may interfere oral drug absorption . 10 . Subjects history intestinal perforation , colitis , clinically significant gastrointestinal bleeding intestinal obstruction within one year prior enrollment . 11 . Subjects sign symptom major disease include , limit : end organ failure , major chronic illness cancer , coagulation disorder , hemolytic condition ( eg , sickle cell disease ) active infection , opinion investigator , make undesirable subject participate study . 12 . Subjects history major cardiac neurologic disease include , limited , angina pectoris , symptomatic coronary artery disease , uncontrolled hypertension ( time study entry ) , New York Heart Association ( NYHA ) Class III IV congestive heart failure , confirm significant cardiac conduction abnormality ( include QTc &gt; 0.45 sec ) arrhythmia , myocardial infarction within 12 month , cerebrovascular accident , transient ischemic attack . 13 . Other condition could jeopardize subject 's ability comply protocol include limited dementia , psychosis , major psychiatric disorder . 14 . Subjects know history hepatitis B C human immunodeficiency ( HIV ) infection . 15 . Subjects require therapeutic dos anticoagulant . 16 . Subjects require use granulocyte colony stimulate factor ( GCSF ) prophylaxis neutropenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>advanced malignancy</keyword>
	<keyword>refractory therapy</keyword>
	<keyword>phase 1</keyword>
</DOC>